Login to Your Account

Other News To Note

Wednesday, January 11, 2012

• Alchemia Ltd., of Brisbane, Australia, said it randomized the first patient in its pivotal Phase III study of HA-Irinotecan, its lead cancer drug that uses the firm's HyACT technology to target irinotecan directly to cancer cells.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription